Top

International Journal of Diabetes in Developing Countries

Published in:

31-08-2023 | Exenatide | Original Article

Early effect of exenatide treatment on atherogenicity in patients with type 2 diabetes mellitus

Authors: Burak Menekşe, Adnan Batman

Published in: International Journal of Diabetes in Developing Countries | Issue 1/2024

Abstract

Objective

Diabetes mellitus is a chronic metabolic disease often associated with hyperlipidemia. High low-density lipoprotein cholesterol (LDLc), high triglyceride, and low high-density lipoprotein cholesterol (HDLc) form the atherogenic lipoprotein profile. In this study, we examined how exenatide, a glucagon-like peptide 1 (GLP-1) analog, affects lipid profile and atherogenic indices in patients with diabetes.

Methods

100 patients diagnosed with type 2 diabetes mellitus (T2DM) participated in this retrospective study. Clinical and laboratory data of the patients were obtained before exenatide treatment and at the 12th week. From the lipid profile, Atherogenicity Plasma Index (AIP), Castelli Risk Index I (CRI-I), Castelli Risk Index II (CRI-II), Atherogenic Coefficient (AC), triglyceride (TG)/HDLc, TG- Glucose index (TyG) and TyG-Body Mass Index (BMI) data were calculated.

Results

There was a significant improvement in body weight (BW), BMI, fasting plasma glucose (FPG), glycosylated hemoglobin (HbA1c), and conventional lipid profile after exenatide treatment. Statistically, significant decreases were observed in atherogenicity indices TyG index, TyG-BMI index, CRI-I, CRI-II, AIP, and AC indices (p < 0.05). This improvement in TG/HDLc, TyG index, CRI-I, CRI-II, AIP and AC indices was independent of HbA1c and BMI. Especially in patients with BMI ≥ 40 kg/m², TyG-BMI index (p:0.01), a statistically significant decrease was observed in TyG index, TyG-BMI index, CRI-I, and AIP values in patients with HbA1c ≥8% (p:0.001, p:0.016, p:0.047, p:0.008).

Conclusion

In addition to its commonly known effects such as lowering FPG levels and weight loss, exenatide has been observed to have a positive effect on traditional lipid profiles and atherogenicity-related indices. In addition to its antidiabetic effect, it should be considered in diabetic patients in treatment options for atherosclerotic cardiovascular prevention.

Martins EB, Lima EB, Pitta FG, et al. Pharmacological therapy and cardiovascular risk reduction for type 2 diabetes. Rev Assoc Med Bras. 2020; https://doi.org/10.1590/1806-9282.66.9.1283.

Klen J, Dolžan V. Glucagon-like peptide-1 receptor agonists in the management of type 2 diabetes mellitus and obesity: The impact of pharmacological properties and genetic factors. Int J Mol Sci. 2022; https://doi.org/10.3390/ijms23073451.

Min T and Bain SC. The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: the SURPASS clinical trials. Diabetes Ther. 2021; https://doi.org/10.1007/s13300-020-00981-0.

Jastreboff AM, Aronne LJ, Ahmad NN, et al., Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022; https://doi.org/10.1056/NEJMoa2206038.

Mirzaei F, Khodadadi I, Majdoub N, et al. Role of glucagon-like peptide-1 (GLP-1) agonists in the management of diabetic patients with or without COVID-19. Open J Med Chem. 2022; https://doi.org/10.2174/18741045-v16-e2212130.

Tamborlane WV, Bishai R, Geller D, et al. Once-weekly exenatide in youth with type 2 diabetes. Diabetes Care 2022; https://doi.org/10.2337/dc21-2275.

Organization WH. WHO European regional obesity report 2022. 2022; World Health Organization. Regional Office for Europe.

Brown E, Wilding JPH, Barber TM, et al. Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities. Obes Rev. 2019; https://doi.org/10.1111/obr.12841.

Fahed G, Aoun L, Zerdan MB, et al. Metabolic syndrome: Updates on pathophysiology and management in 2021. Int J Mol Sci. 2022; https://doi.org/10.3390/ijms23020786.

10.

Vekic J, Zeljkovic A, Cicero AFG, et al. Atherosclerosis development and progression: the role of atherogenic small, dense LDL. Medicina. 2022; https://doi.org/10.3390/medicina58020299.

11.

Zhu X, Yu L, Zhou H, et al. Atherogenic index of plasma is a novel and better biomarker associated with obesity: a population-based cross-sectional study in China. Lipids Health Dis. 2018; https://doi.org/10.1186/s12944-018-0686-8.

12.

Abid HA, ZS Abid, and Abid SA. Atherogenic indices in clinical practice and biomedical research: a short review. Baghdad J Biochem Appl Biol Sci. 2021; 10.47419/bjbabs.v2i02.52.

13.

Si Y, Fan W, Han C, et al. Atherogenic index of plasma, triglyceride-glucose index and monocyte-to-lymphocyte ratio for predicting subclinical coronary artery disease. Am J Med Sci. 2021; https://doi.org/10.1016/j.amjms.2021.05.001.

14.

Xing Y, Chen J, Liu J, Ma H. Associations between GGT/HDL and MAFLD: a cross-sectional study. Diabetes Metab Syndr Obes. 2022;15:383–94.CrossRefPubMedPubMedCentral

15.

Berberich AJ, Hegele RA. Lipid effects of glucagon-like peptide 1 receptor analogs. Curr Opin Lipidol 2021; https://doi.org/10.1097/MOL.0000000000000750.

16.

Andrikou E, Tsioufis C, Andrikou I, et al. GLP-1 receptor agonists and cardiovascular outcome trials: an update. Hell J Cardiol 2019; https://doi.org/10.1016/j.hjc.2018.11.008.

17.

Vekic J, Zeljkovic A, Rasadi KA, et al. A new look at novel cardiovascular risk biomarkers: the role of atherogenic lipoproteins and innovative antidiabetic therapies. Metabolites. 2022; https://doi.org/10.3390/metabo12020108.

18.

Matikainen N, Söderlund S, Björnson E, et al. Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-centre randomized controlled study. Diabetes Obes Metab. 2019; https://doi.org/10.1111/dom.13487.

19.

Hjerpsted JB, Flint A, Brooks A, et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes Obes Metab. 2018; https://doi.org/10.1111/dom.13120.

20.

Giorgino F, Shaunik A, Liu M, Saremi A. Achievement of glycaemic control is associated with improvements in lipid profile with iGlarLixi versus iGlar: A post hoc analysis of the LixiLan-L trial. Diabetes Obes Metab. 2019; https://doi.org/10.1111/dom.13857.

21.

Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017; https://doi.org/10.1056/NEJMoa1612917.

22.

Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016; https://doi.org/10.1056/NEJMoa1607141.

23.

Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016; https://doi.org/10.1056/NEJMoa1603827.

24.

Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018; https://doi.org/10.1016/S0140-6736(18)32261-X.

25.

Bhardwaj S, Bhattacharjee J, Bhatnagar MK, Tyagi S. Atherogenic index of plasma, castelli risk index and atherogenic coefficient-new parameters in assessing cardiovascular risk. Int J Pharm Biol Sci. 2013;3(3):359–64.

26.

Yang G, Lei Y, Inoue A, et al. Exenatide mitigated diet-induced vascular aging and atherosclerotic plaque growth in ApoE-deficient mice under chronic stress. Atherosclerosis. 2017; https://doi.org/10.1016/j.atherosclerosis.2017.07.014.

27.

Nikolic D, Giglo RV, Rizvi AA, et al. Liraglutide reduces carotid intima-media thickness by reducing small dense low-density lipoproteins in a real-world setting of patients with type 2 diabetes: A novel anti-atherogenic effect. Diabetes Ther. 2021; https://doi.org/10.1007/s13300-020-00962-3.

Title: Early effect of exenatide treatment on atherogenicity in patients with type 2 diabetes mellitus
Authors: Burak Menekşe
Adnan Batman
Publication date: 31-08-2023
Publisher: Springer India
Keywords: Exenatide
Diabetes
Type 2 Diabetes
Incretin Mimetics
Incretin Mimetics
Published in: International Journal of Diabetes in Developing Countries / Issue 1/2024
Print ISSN: 0973-3930
Electronic ISSN: 1998-3832
DOI: https://doi.org/10.1007/s13410-023-01233-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2024

The relationship between neuron-specific enolase, high sensitivity C reactive protein, and diabetic peripheral neuropathy in Chinese patients with type 2 diabetes: A prospective nested case–control analysis

A randomized, double-blind, active-controlled trial assessing the efficacy and safety of a fixed-dose combination (FDC) of MEtformin hydrochloride 1000 mg ER, SItagliptin phosphate 100 mg, and DApagliflozin propanediol 10 mg in Indian adults with type 2 diabetes: The MESIDA trial

Role of sensory feedback in postural control of the patients with diabetic neuropathy

Association between comorbid diabetes mellitus and mortality of patients with sepsis: A meta-analysis

Correction to: Basic fibroblast growth factor alleviates metabolic abnormalities in the heart of streptozotocin-induced diabetic rats

Diabetes-specific eating disorder and social exclusion in adolescents with type 1 diabetes

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials